Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384322 | 1.00 | SCN9A (0.60) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL30663629 | 1.00 | SCN9A (0.60) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL17500269 | 0.91 | SCN9A (0.69) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL16645246 | 0.90 | MTNR1A (0.58) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL17938401 | 0.90 | MTNR1A (0.58) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL17500231 | 0.89 | SCN9A (0.67) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL18029114 | 0.86 | KMT2A (0.61) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL10956670 | 0.86 | SCN9A (0.65) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL1460679 | 0.86 | KMT2A (0.61) | SCN9AHTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL1460676 | 0.86 | KMT2A (0.61) | SCN9AHTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872721-B2 | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1′,2′:1,6]pyrido[3,4b]-indole-1,4-dione | LILLY ICOS LLC (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030225092-A1 | Chemical compounds | LILLY ICOS LLC | 2003-12-04 | — | — | US | disclosed |
| EP-1289989-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | Lilly Icos LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094345-A2 | DERIVATIVES OF 2,3,6,7,12,12A-HEXAHYDROPYRAZINO[1',2':1,6]PYRIDO[3,4-B]INDOLE-1,4-DIONE | LILLY ICOS LLC (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225092-A1 | Chemical compounds | ABCG2, SDHA, CYP11B1 | SCN9A 1818/4885HTR2A 3535/4885HTR1A 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.